Sleep

Latest News


CME Content


Many sleepwalkers who injure themselves during their sleep do not experience pain until the next morning, which may lead them to the pharmacy for OTC pain relief.

The FDA has approved Merck's Belsomra (suvorexant), a Schedule IV substance, for the treatment of insomnia, as characterized by difficulties with sleep onset and/or sleep maintenance.